

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International BureauReference No.: BS
Filing Date: February 28, 2002
Application No.: 10/085,418

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12N 15/33, 15/11, 15/82, 5/10, A01H 5/00, A01N 65/00	A1	(11) International Publication Number: WO 95/09920 (43) International Publication Date: 13 April 1995 (13.04.95)
(21) International Application Number: PCT/EP94/03295 (22) International Filing Date: 5 October 1994 (05.10.94) (30) Priority Data: 9320548.2 6 October 1993 (06.10.93) GB (71) Applicant (for all designated States except AT DE US): SANDOZ LTD. [CH/CH]; Lichtstrasse 35, CH-4002 Basle (CH). (71) Applicant (for DE only): SANDOZ-PATENT-GMBH [DE/DE]; Humboldtstrasse 3, D-79539 L�rrach (DE). (71) Applicant (for AT only): SANDOZ ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT). (72) Inventor; and (75) Inventor/Applicant (for US only): DE HAAN, Petrus, Theodorus [NL/NL]; Kruidedeel 34, NL-1602 GL Enkhuizen (NL). (74) Common Representative: SANDOZ LTD.; Patents & Trade-marks Div., Lichtstrasse 35, CH-4002 Basle (CH).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: VIRUS RESISTANT OR TOLERANT CELLS (57) Abstract A nucleotide sequence comprising a transcriptional regulatory sequence and a sequence contiguous therewith and under the transcriptional control thereof, which contiguous sequence encodes an RNA which consists of a plurality of sub-sequences, characterized in that at least two of the sub-sequences have the sequences of viral RNAs and the RNA contains at least one translational stop codon located upstream of the 3' terminal sub-sequence. It is preferred that at least one of the sub-sequences is in an anti-sense configuration with respect to virus RNA, and that the contiguous sequence encodes mRNA. The invention also includes, <i>inter alia</i> , the use of such a sequence in the generation of virus resistant or tolerant plants, and such plants comprising the sequence.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LV	Latvia	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

VIRUS RESISTANT OR TOLERANT CELLS

The present invention relates to cells having a genetically engineered reduced susceptibility to viruses, processes for obtaining such cells, and genetic material capable of generating such reduced susceptibility. In a preferred embodiment the cells are plant cells.

Numerous attempts have been made to engineer viral resistance into plants by inserting DNA-containing vectors into acceptor plant tissue, which DNA is capable of encoding viral proteins in the thus transformed plant. The viral protein may confer resistance to an invading virus comprising a viral protein substantially the same as that encoded by the introduced DNA. Other attempts at engineering virus resistance in plants use anti-sense RNA which relies on the introduction of DNA encoding an RNA strand which is complementary to the RNA of an invading virus and thus interferes with the replication thereof. Plants displaying a broad degree of reduced susceptibility, i.e. to more than one viral type, or a greater degree of reduced susceptibility to a particular virus type, are highly desirable.

Resistance in plants to multiple virus types may be obtained by transforming plant tissue with DNA constructs made up of individual blocks of genetic elements, each element consisting essentially of three components: (i) promoter - (ii) virus resistance conferring genetic element - (iii) terminator. However, such constructs require the building in of many promoters and terminators and typically suffer from genetic instability.

The present invention provides *inter alia*, novel nucleotide sequences which can be used in the production of eukaryotic cells - particularly plant cells - which exhibit an improved resistance or tolerance to viruses. Such improvements surprisingly correlate primarily with the levels of the RNA and sub-sequences thereof encoded by the nucleotide sequence of the invention, rather than the levels of the translation products of such RNA. Indeed, improved resistance or tolerance may be obtained by transcription of the present inventive nucleotide sequences in eukaryotic cells, substantially in the absence of the translation of such transcription products.

According to the present invention there is provided a nucleotide sequence (nucleotide sequence according to the invention) comprising a transcriptional regulatory sequence and a sequence contiguous therewith and under the transcriptional control thereof, which contiguous sequence encodes an RNA which consists of a plurality of sub-sequences, characterized in that at least two of the sub-sequences have the sequences of viral RNAs and the RNA contains at least one translational stop codon located upstream of the 3' terminal sub-sequence.

Each of the sub-sequences may be responsible for conferring a reduced susceptibility to a virus in plant cells or for conferring an enhanced reduced susceptibility to a single virus type in plant cells. Such sub-sequences need not necessarily be capable of encoding protein, and it is preferred that at least one of them is incapable of encoding protein as a consequence of the RNA lacking a translational start codon at the 5' thereof and/or the contiguous sequence encoding a second sub-sequence down stream from a first sequence, the second sequence defining a translational reading frame which is out of phase with that defined by the first sub-sequence.

The said nucleotide sequence may encode an RNA having any number of sub-sequences. It is preferred that the number of sub-sequences is between 2 and 7 (inclusive) and still more preferred that the number is likewise between 2 and 4.

At least one of the sub-sequences may be in an anti-sense configuration with respect to virus RNA. The contiguous sequence may encode mRNA.

It is preferred that at least one of the sub-sequences is a cistron. By "cistron" is meant an RNA which contains a translation open reading frame, i.e. one that comprises a translation start codon, protein encoding sequence and a translation stop codon.

It is preferred that the RNA encoded by the contiguous sequence comprises at least one ribozyme (or other cleavage site) between two of the sub-sequences so that the RNA can be cleaved into regions comprising the said sub-sequences, or even into the sub-sequences *per se*. Except in the case of the most 5' of the sub-sequences contained within the RNA

encoded by the contiguous sequence, the nucleotide sequences resulting from such cleavage will not contain a 5'cap or a ribosome binding site and will thus not be translated when present in a Eukaryotic cell.

It is more preferred that at least one of the sub-sequences encodes a viral coat protein or a viral nucleocapsid protein, for example, the nucleocapsid (N) protein of a tospovirus such as tomato spotted wilt virus (TSWV), tomato chlorotic spot virus (TCSV), groundnut ringspot virus (GRSV), groundnut bud necrosis virus (GBNV), or Impatiens necrotic spot virus (INSV). Other viral proteins which may be encoded by the sub-sequences present in the RNA encoded by the contiguous sequence include viral replicases, movement proteins and the like derived from virus sources such as tospoviruses, potyviruses, potexviruses, tobamoviruses, luteoviruses, cucumoviruses, bromoviruses, closteroviruses, tombusviruses and furoviruses.

The invention still further provides a nucleotide sequence which is similar to the above disclosed sequence. By "similar" is meant a test sequence which is capable of hybridizing to a sequence which is complementary to the inventive nucleotide sequence. When the test and inventive sequences are double stranded the nucleic acid constituting the test sequence preferably has a T_m within 20°C of that of the inventive sequence. In the case that the test and inventive sequences are mixed together and denatured simultaneously, the T_m values of the sequences are preferably within 10°C of each other. More preferably the hybridization is performed under stringent conditions, with either the test or inventive DNA preferably being supported. Thus either a denatured test or inventive sequence is preferably first bound to a support and hybridization is effected for a specified period of time at a temperature of between 50 and 70°C in double strength citrate buffered saline containing 0.1% SDS followed by rinsing of the support at the same temperature but with a buffer having a reduced SC concentration. Depending upon the degree of stringency required, and thus the degree of similarity of the sequences, such reduced concentration buffers are typically single strength SC containing 0.1% SDS, half strength SC containing 0.1% SDS and one tenth strength SC containing 0.1% SDS. Sequences having the greatest degree of similarity are those the hybridization of which is least affected by washing in buffers of reduced concentration. It is most preferred that the test and inventive sequences are so

similar that the hybridization between them is substantially unaffected by washing or incubation in one tenth strength sodium citrate buffer containing 0.1%SDS.

The invention still further provides a nucleotide sequence which is complementary to one which hybridizes under stringent conditions with the above disclosed nucleotide sequences.

The invention also provides a DNA construct comprising the nucleotide sequence according to the invention, as well as a biological vector comprising the said sequence or construct. The biological vector may be a virus or a bacterium, such as *Agrobacterium tumefaciens*, for example, and the construct advantageously further encodes protein having herbicide resistance, plant growth-promoting, anti-fungal, anti bacterial, and/or anti-nematode properties.

The invention still further provides eukaryotic cells, such as plant cells (including protoplasts) for example, containing the said nucleotide sequence, construct or vector.

The invention still further provides plants comprising such plant cells, the progeny of such plants which contain the sequence stably incorporated and heritable in a Mendelian manner, and/or the seeds of such plants or such progeny. Such plants include field crops, vegetables and fruits including tomato, pepper, melon, lettuce, cauliflower, broccoli, cabbage, brussels sprout, sugar beet, corn, sweetcorn, onion, carrot, leek, cucumber, tobacco, alfalfa, aubergine, beet, broad bean, celery, chicory, cow pea, endive, gourd, groundnut, papaya, pea, peanut, pineapple, potato, safflower, snap bean, soybean, spinach, squashes, sunflower, sorghum, water-melon and the like; and ornamental crops including Impatiens, Begonia, Petunia, Pelargonium, Viola, Cyclamen, Verbena, Vinca, Tagetes, Primula, Saint Paulia, Ageratum, Amaranthus, Anthirrhinum, Aquilegia, Chrysanthemum, Cineraria, Clover, Cosmo, Cowpea, Dahlia, Datura, Delphinium, Gerbera, Gladiolus, Gloxinia, Hippeastrum, Mesembryanthemum, Salpiglossis, Zinnia, and the like.

The invention still further provides the use of the sequence according to the invention, - whether "naked" or present in a DNA construct or biological vector - in the production of virus resistant or tolerant eukaryotic cells. By "resistant" is meant a cell which exhibits

substantially no phenotypic changes as a consequence of infection with the virus. By "tolerant" is meant a cell which, although it may exhibit some phenotypic changes as a consequence of infection with a virus, does not have a substantially decreased reproductive capacity or substantially altered metabolism. Such use leads to the production of morphologically normal virus resistant or tolerant whole plants.

The invention still further provides a method of inducing resistance or tolerance to viruses in eukaryotic cells comprising introducing into such cells a nucleotide sequence according to the invention, or a construct or vector containing it. It is preferred that the cells are plant cells as indicated above.

The invention still further provides a method of inhibiting the production of at least one enzyme in a eukaryotic cell comprising introducing into the said cell a nucleotide sequence comprising a transcriptional regulatory sequence and a sequence contiguous therewith and under the transcriptional control thereof, which contiguous sequence encodes an RNA which consists of a plurality of sub-sequences, characterized in that the RNA encoded by the contiguous sequence contains at least one translational stop codon located upstream of the 3' terminal sub-sequence. In a further embodiment of the method, at least one of the sub-sequences is in an anti-sense configuration with respect to the coding sequence in the host cell mRNA which encodes the said enzyme. The enzyme may be of viral origin and present in the cell as a consequence of the viral infection thereof.

The invention will be further apparent from the following description taken in conjunction with associated drawings and sequence listings.

Figure 1 shows a schematic representation of constructs comprising possible nucleotide sequences according to the invention, in which the contiguous sequence encodes an RNA comprising sub-sequences encoding the nucleocapsid proteins of TCSV, TWSV and GRSV.

Figure 2 shows a schematic representation of constructs comprising possible nucleotide sequences according to the invention, in which the contiguous sequence encodes an RNA comprising sub-sequences encoding the nucleocapsid proteins of TCSV and TSWV and the

coat protein of PVY.

SEQ ID No. 1 shows a DNA sequence encoding the nucleocapsid proteins of GRSV, TSWV, and TCSV; SEQ ID No. 2 shows a DNA sequence substantially similar to that given in SEQ ID No. 1, except that each of the sub-sequences encoding the nucleocapsid proteins is bordered by a ribozyme sequence rendering the RNA encoded by the DNA sequence susceptible to cleavage at pre-determined sites; SEQ ID No. 3 shows a DNA sequence encoding TCSV and TSWV nucleocapsid proteins and the coat protein of potato virus Yⁿ (PVY); SEQ ID No. 4 shows a first primer sequence designated ZUP422 (see below) and SEQ ID No. 5 shows a second primer sequence designated ZUP423 (see below).

Examples of the nucleotide sequences of the invention are provided below. These examples relate to the production of virus resistant or tolerant tomato plants. Tomato plants may be attacked by both the cucumber mosaic virus (CMV) and the tomato spotted wilt virus (TSWV). Enhanced resistance or tolerance to these viruses may be produced in a number of ways by introducing various embodiments of the nucleotide sequence of the invention into the plants, or the progenitor material thereof.

1. The contiguous sequence in the nucleotide sequence of the invention may encode an mRNA which consists - in the 5' to 3' direction - of (i) a translation start codon, (ii) the coding region of the nucleocapsid protein of TSWV, (iii) a translation stop codon, (iv) optionally a further start codon, (v) the coding region of the CMV replicase and (vi) optionally a further stop codon. When such a sequence is introduced into the cells of tomato plants, the sequence encoding the mRNA is transcribed. The region of the thus transcribed mRNA which encodes the TSWV nucleocapsid protein is translated, whilst the region of the mRNA which encodes the CMV replicase is not translated as a result of translation ceasing at the stop codon on the 3' side of the coding region of the TSWV nucleocapsid protein.

2. The contiguous sequence in the nucleotide sequence of the invention may encode an mRNA which consists - in the 5' to 3' direction - of (i) a translation start codon, (ii) the

coding region of the CMV coat protein, (iii) a translation stop codon, (iv) optionally a further start codon, (v) a region encoding the nucleocapsid protein of TSWV and (vi) optionally a further stop codon. When such a sequence is introduced into the cells of tomato plants, the sequence encoding the mRNA is transcribed. The region of the thus transcribed mRNA which encodes the CMV coat protein is translated, whilst the region of the mRNA which encodes the nucleocapsid protein of TSWV is not translated as a result of translation ceasing at the stop codon on the 3' side of the region encoding the CMV coat protein.

3. The contiguous sequence in the nucleotide sequence of the invention may encode an RNA which consists - in the 5' to 3' direction - of (i) the coding region of the CMV coat protein, (ii) a translation stop codon, (iii) optionally a further start codon, (iv) a region encoding the nucleocapsid protein of TSWV and (v) optionally a further stop codon. When such a sequence is introduced into the cells of tomato plants, the sequence encoding the RNA is transcribed, but the RNA is not translated *inter alia* because the first cistron does not contain a translation start codon upstream of the translational stop codon, even assuming that the RNA contains a 5' cap to which ribosomes could bind. The skilled man is aware that eukaryotic cells do not translate second and subsequent cistrons in polycistronic mRNA if the first cistron possesses a stop codon.

4. The contiguous sequence in the nucleotide sequence of the invention may encode an mRNA which consists - in the 5' to 3' direction - of (i) a translational start codon (ii) the coding region of the CMV coat protein, (iii) a translation stop codon, (iv) optionally a further start codon, (v) a region encoding the nucleocapsid protein of TSWV in an antisense configuration with respect to mRNA which encodes the TSWV nucleocapsid protein, (vi) optionally a further stop codon. When such a sequence is introduced into the cells of tomato plants, the sequence encoding the mRNA is transcribed. The region of the thus transcribed mRNA which encodes the CMV coat protein is translated, whilst the region of the mRNA which encodes the nucleocapsid protein of TSWV is not translated as a result of translation ceasing at the stop codon on the 3' side of the region encoding the CMV coat protein. The region of the non-translated mRNA which contains the said anti-sense RNA is capable of base pairing with the mRNA encoding the TSWV nucleocapsid protein.

It will be appreciated that the contiguous sequence may encode an RNA comprising sub-sequences, two or more of which have sequences derived from a common virus type, so that still greater resistance to virus infection can be generated. For example:

6. The contiguous sequence in the nucleotide sequence of the invention may encode an mRNA which consists - in the 5' to 3' direction - of (i) a translational start codon (ii) the coding region of the TSWV replicase, (iii) a translation stop codon, (iv) optionally a further start codon, (v) a region encoding the nucleocapsid protein of TSWV, (vi) optionally a further stop codon. When such a sequence is introduced into the cells of tomato plants, the sequence encoding the mRNA is transcribed. The region of the thus transcribed mRNA which encodes the replicase is translated, whilst the region of the mRNA which encodes the nucleocapsid protein of TSWV is not translated as a result of translation ceasing at the stop codon on the 3' side of the region encoding the TSWV replicase.

7. The contiguous sequence in the nucleotide sequence of the invention may encode an mRNA which consists - in the 5' to 3' direction - of (i) a translational start codon (ii) a region encoding a first nucleocapsid protein of TSWV, (iii) a translation stop codon, (iv) optionally a further start codon, (v) a region encoding a second nucleocapsid protein of TSWV, (vi) optionally a further stop codon. When such a sequence is introduced into the cells of tomato plants, the sequence encoding the mRNA is transcribed. The region of the thus transcribed mRNA which encodes the first nucleocapsid protein is translated, whilst the region of the mRNA which encodes the second nucleocapsid protein is not translated as a result of translation ceasing at the stop codon on the 3' side of the region encoding the first protein. If desirable, the translational start codon on the 5' side of the region encoding the first nucleocapsid protein may be deleted.

The following discussion details the production of nucleotide sequences according to the invention, their insertion into appropriate vectors, transformation of plant material with such vectors, and the regeneration of such transformed material into virus resistant or tolerant morphologically normal whole plants.

Cultivation of plant material and bacterial strains, and generation of vectors

Cultivars of *Nicotinic tabacum* and *Lycopersicon esculentum*, used in plant transformation studies, are grown under standard greenhouse conditions. Axenic explant material is grown on standard MS media [Murashige and Skoog (1962). *Physiol. Plant* 15: 473] containing phytohormones and sucrose at appropriate concentrations.

E. coli is grown on rotary shakers at 37° C in standard LB-medium. *Agrobacterium tumefaciens* strains are grown at 28°C in Min. A medium supplemented with 0.1 % glucose [Ausubel *et al.*, (1987). *Current Protocols in Molecular Biology*, Green Publishing Associates and Wiley Intersciences].

In all cloning procedures, *E. coli* strain JM83, (F, Δ (lac-pro), ara, rpsL, Ø80, dlacZM15) is used as the recipient for recombinant plasmids.

Binary vectors are conjugated to *Agrobacterium tumefaciens* strain LBA 4404, a strain containing the Ti-plasmid vir region, [Hoekema *et al.* (1983) *Nature* 303: 179] in standard triparental matings using *E. coli* HB101 containing the plasmid pRK2013 as a helper strain [Figurski and Helsinki, (1979) *PNAS* 76: 1648]. Appropriate *A. tumefaciens* recipients are selected on media containing rifampicin (50 µg/ml) and kanamycin (50 µg/ml).

Cloning of fragments in the vectors pUC19 [Yanish-Perron *et al.* (1985) *Gene* 33: 103], pBluescript (Stratagene), pBIN19 [Bevan *et al.* (1984) *Nucl. Acids Res.* 12: 8711] or derivatives thereof, restriction enzyme analysis of DNA, transformation of *E. coli* recipient strains, isolation of plasmid DNA on small as well as large scale, nick-translation, *in vitro* transcription, DNA sequencing, Southern blotting and DNA gel electrophoresis are performed according to standard procedures [Maniatis *et al.* (1982) *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory, New York; Ausubel *et al.* *supra*, (1987)].

Collection of cDNA clones to Nucleocapsid (N) genes of different tospoviruses and to the Coat Protein (CP) gene of PVY

A recombinant pUC19-derived plasmid containing the TSWV N gene is described by De Haan *et al.* (1990) *J. Gen. Virology* 71: 001. Recombinant pBluescript-derived plasmids

containing the TCSV N gene, and GRSV N genes are described by De Avila *et al.* (1993) J. Gen. Virology 74: 153. A recombinant pUC19-derived plasmid containing the PVY CP gene is described by Van der Vlugt (1992). PhD thesis, Agricultural University Wageningen, The Netherlands, Ch4; pages 45-47.

Construction of expression vectors pZU-C and pZU-D

Expression vectors pZU-C and pZU-D are derivatives of pZU-B described in European patent publication No. EP-A 426 195. The unique SmaI cloning site between the TMV Ω sequence and the NOS terminator is replaced using standard laboratory techniques [Maniatis *et al* *supr*, (1982); Ausubel *et al* (1987) *surpra*] by an NcoI cloning site, yielding pZU-C. pZU-C is linearized with PstI and treated with T4 DNA polymerase to obtain blunt ends. BamHI linkers are ligated and the plasmid is digested with BamHI and subsequently recircularized using T4 DNA ligase resulting in recombinant plasmid pZU-D. The recombinant plasmids pZU-C and pZU-D contain the 35S HincII-TMV Ω fusion (35S- Ω), unique NcoI, PstI (pZU-C) or NcoI, BamHI (pZU-D) sites and the NOS terminator.

Construction of a plant transformation vector containing three tospoviral N genes

The recombinant pUC19-derived plasmid containing the GRSV N gene is linearized with BamHI and treated with T4 DNA polymerase to obtain blunt ends. SstI linkers are ligated and the plasmid is digested with SstI and subsequently recircularized using T4 DNA ligase. The resulting plasmid is then linearized with KpnI and treated with T4 DNA polymerase to obtain blunt ends. BamHI linkers are ligated and the plasmid is digested with BamHI and subsequently recircularized using T4 DNA ligase resulting in recombinant plasmid GRSV N (Fig. 1), containing the GRSV N gene (nucleotides 1986 through to 2953 SEQ ID No. 1). Plasmid GRSV N is subjected to SstI digestion and the fragment containing the GRSV N gene is separated electrophoretically and purified from the gel using an NA-45 (Schleicher and Schüll) DEAE membrane and cloned into SstI linearized TCSV N (a pBluescript-derived recombinant plasmid) containing the TCSV N gene (nucleotides 7 through to 981 SEQ ID No. 1) resulting in TCSV N- GRSV N. Plasmid TSWV N is subjected to KpnI digestion and the fragment containing the TSWV N gene (nucleotides 988 through to 1930 SEQ ID No. 1) is separated electrophoretically and purified from the

gel using an NA-45 DEAE membrane and cloned into Kpn1 linearized TCSV N- GRSV N, resulting in the recombinant plasmid TCSV N - TSWV N -GRSV N (Fig. 1) Plasmid TCSV N - TSWV N - GRSV N (SEQ ID No. 1) is subjected to BamH1 digestion and the fragment containing the tospoviral N genes, is separated electrophoretically and purified from the gel using an NA-45 DEAE membrane and cloned into BamH1 linearized pZU-D, resulting in pTOSPON 1 (Fig. 1). The nucleotide sequence containing the 35S- Ω promoter, the tosporival N genes and the NOS terminator is excised from the plasmid pTOSPON 1 via a partial Sst1 digestion. The isolated gene cassette is then inserted into the Sst1 linearized pBIN19 to create the binary transformation vector pBIN-TOSPON 1.

Construction of a plant transformation vector containing three tospoviral N genes flanked by ribozyme sequences

The nucleotide sequence of DNA encoding the RNA which encodes the three tospoviral nucleocapsid sequences contains ribozyme sequences and is depicted in SEQ ID No. 2.

Two primers are constructed, ZUP422 (depicted in SEQ ID No. 4) and ZUP423 (depicted in SEQ ID No. 5) containing Kpn1 cloning sites, the active ribozyme sequence of the tobacco ringspot virus satellite RNA and 17 nucleotides overlap to the coding region of the TSWV N gene. The primers are used to PCR amplify the TSWV N gene using pTOSPON as a template. The PCR fragment is made blunt-ended by treatment with T4 DNA polymerase and subsequently cloned in the EcoR V site of plasmid pSK+. Clones are obtained, which contain a Kpn1 insertion of the expected size. Sequence analysis reveals that the Kpn1 site originating from primer ZUP422 is destroyed. Therefore, the Kpn1 site located on the multilinker of pSK+, together with the Kpn1 site originating from primer ZUP423 are used to replace the TSWV N gene (as a Kpn 1 fragment) located on the recombinant plasmid TCSV N - TSWV N GRSV N (see above), yielding plasmids TCSV N - ribozyme - TSWV N - ribozyme - GRSV N and TCSV N - ribozyme - TSWV N antisense - ribozyme - GRSV N. These plasmids are linearized with BamH1 and used as templates to produce run-off transcripts with T7 RNA polymerase. Polyacrylamide gel electrophoresis reveals that the primary transcripts are immediately and completely cleaved to yield the separate sense and/or tospoviral N gene molecules. Plasmids TCSV N - ribozyme - TSWV N - ribozyme -GRSV N and TCSV N - ribozyme - TSWV N antisense

- ribozyme - GRSV N (SEQ ID No. 2) are subjected to BamH1 digestion and the fragments containing the tospoviral N genes are separated electrophoretically and purified from the gel using an NA-45 DEAE membrane and cloned into BamH1 linearized pZU-D, resulting in pTOSPON-ribo1 and pTOSPON-ribo2 (Fig. 1) respectively. The nucleotide sequences containing the 35S- Ω promoter, the tospoviral N genes bordered by ribozymes, and the NOS terminator are excised from the plasmids via a partial Sst1 digestion. The isolated gene cassettes are then inserted into the Sst1 linearized pBIN19 to create the binary transformation vectors pBIN-TOSPON-ribo1 and pBIN-TOSPON-ribo2 respectively.

Both constructs are transferred to plants yielding 23 pBIN-TOSPON-ribo1 and 17 pBIN-TOSPON-ribo2 transformants. The progeny of the transformants is challenged with the various tospoviruses and found to exhibit an improved resistance or tolerance thereto, in comparison with non-transformed controls.

Construction of a plant transformation vector containing two tospoviral N genes and the CP gene of PVY

Plasmid TCSV N is subjected to digestion with Pst1 and the large fragment containing the TCSV N gene and pUC19 is separated electrophoretically and purified from the gel using a DEAE membrane (NA-45, Schleicher and Schüll) and recircularized using T4 DNA ligase, resulting in TCSV N (Fig. 2). The recombinant pUC19-derived plasmid containing the pVY CP gene (nucleotides 1984 through to 2899 SEQ ID No. 3) is linearized with Sph1 and treated with T4 DNA polymerase to obtain blunt ends. Sst1 linkers are ligated and the plasmid is digested with Sst1 and subsequently re-circularized using T4 DNA ligase, resulting in recombinant plasmid PVY CP (Fig. 2). Plasmid PVY CP is subjected to Sst1 digestion and the fragment containing the PVY CP gene is separated electrophoretically and purified from the gel using an NA-45 DEAE membrane and cloned into Sst1 linearized TCSV N, resulting in TCSV N - PVY CP. Plasmid TSWV N is subjected to Kpn1 digestion and the fragment containing the TSWV N gene (Fig. 2) is separated electrophoretically and purified from the gel using an NA-45 DEAE membrane and cloned into Kpn1 linearized TCSV N - PVY CP, resulting in the recombinant plasmid TCSV N - TSWV N - PVY CP. Plasmid TCSV N - TSWV N - PVY CP is subjected to Pst1 digestion and the fragment containing the tospoviral N genes and the PVY CP gene is separated electrophoretically and

purified from the gel using an NA-45 DEAE membrane and cloned into Pst1 linearized pZU-C, resulting in pTOSPOPVY 1 (Fig. 2). The gene cassette containing the 35S- Ω promoter, TCSV and TSWV N genes, the PVY CP gene and the NOS terminator is excised from the plasmid pTOSPOPVY 1 via a partial Sst1 digestion. The isolated gene cassette is then inserted into the Sst1 linearized pBIN19 to create the binary transformation vector pBIN-TOSPOPVY 1.

Introduction of binary vectors to tobacco and tomato plant material

Methods to transfer binary vectors to plant material are known to a person skilled in the art. Variations in procedures exist due to differences in *Agrobacterium* strains used, different sources of explant material, differences in regeneration systems, and on the cultivar of plant species employed.

Binary plant transformation vectors as described above are employed in plant transformation experiments according to the following procedures. Binary vector constructs are transferred by tri-parental mating to an acceptor *Agrobacterium tumefaciens* strain, followed by southern analysis of exconjugants for verification of proper transfer of the construct to the acceptor strain, inoculation and cocultivation of axenic explant material with *Agrobacterium tumefaciens* strain of choice, selective killing of the *Agrobacterium tumefaciens* used with appropriate antibiotics, selection of transformed cells by growing on selective media containing kanamycin, transfer of tissue to shoot-inducing media, transfer of selected shoots to root induction media, transfer of plantlets to soil, assaying for intactness of the construct by southern analyses of isolated total DNA from the transgenic plant, assaying for proper function of the inserted gene by northern analysis and/or enzyme assays and western blot analysis of proteins following methods as described by Ausubel *et al.* supra.

Expression of DNA sequences in tobacco and tomato plant cells

RNA is extracted from leaves of regenerated plants using the following protocol. 200 mg leaf material is ground to a fine powder in liquid nitrogen. 800 μ l RNA extraction buffer (100 mM Tris-HCl (pH 8.0), 500 mM NaCl, 2 mM EDTA, 200 nM β -Mercapto-ethanol, 0.4 % SDS) is added and the homogenate extracted with phenol, and nucleic acids collected

by alcohol precipitation. Nucleic acids are re-suspended in 0.5ml 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, and LiCl is added to a final concentration of 2M, and left on ice for no longer than 4 hours. The RNA is collected by centrifugation and re-suspended in 400 µl 10 mM Tris-HCl (pH 8.0), 1 mM EDTA and then precipitated with alcohol. The RNA is then re-suspended in 50 µl 10 mM Tris-HCl (pH 8.0), 1 mM EDTA. RNAs are separated on glyoxal/agarose gels and blotted to Genescreen as described by van Grinsven *et al.* [(1986) Theor. Appl. Gen. 73:94-101]. Recombinant viral RNA sequences are detected using DNA or RNA probes labeled with [³²P], [³⁵S] or by using non-radioactive labeling techniques. Based on northern analysis, it is determined to what extent the regenerated plants express recombinant viral genes.

Plants transformed with recombinant viral DNA molecules are also subjected to Western blot analysis after inoculation of the plant with the respective virus. Proteins are extracted from leaves of transformed plants by grinding in sample buffer [Laemmli (1970) Nature 244: 29] and a 50 µg portion of protein is subjected to electrophoresis in a 12.5 % SDS-polyacrylamide gel. Separated proteins are transferred to nitrocellulose electrophoretically as described by Towbin *et al.* [(1979) PNAS 76: 4350]. Transferred proteins are reacted with anti-serum raised against purified TCSV nucleocapsids. Based on the results of the Western analysis it is determined that transformed plants express TCSV protein.

Resistance of tobacco and tomato plants against tospoviral and/or potyviral infection

Transformed plants are grown in the greenhouse under standard quarantine conditions in order to prevent any infections by undesirable pathogens. The transformants are self-pollinated and the seeds harvested. Progeny plants are analyzed for segregation of the inserted gene and are subsequently infected with TCSV, TSWV, and/or GRSV and PVY by mechanical inoculation. Tissue from plants systemically infected with these viruses is ground in 5 volumes of ice-cold inoculation buffer (10 mM phosphate buffer, containing 10 mM sodium sulphite) and rubbed in the presence of carborundum powder on the first two fully extended leaves of approximately 5 week old seedlings. Inoculated plants are monitored for symptom development for 3 weeks after inoculation.

Plants containing TOSPON 1 (Fig. 1), pTOSPON-ribo1, pTOSPON-ribo2 or TOSPOPVY 1 (Fig. 2) sequences show reduced susceptibility to infection with TCSV, TSWV, and/or GRSV and PVY compared with untransformed control plants which show severe systemic symptoms within 7 days after inoculation with these viruses. Plants that resisted infection are self pollinated and the like resistance of the resulting S2 progeny is demonstrated.

It will be appreciated that the present invention is not limited to the above examples only, but includes all logical and obvious extensions of the embodiments of the invention disclosed herein as well as those specifically claimed. Thus the invention also includes the embodiments indicated in the next paragraph in the clauses numbered 1-12.

- (1). Multigene DNA constructs comprising at least one non-structural gene wherein the multigene DNA is under the control of a single set of genetic regulatory elements. By "non-structural gene" is meant a gene capable of coding for a viral RNA molecule which is substantially incapable of encoding for a viral polypeptide or protein but which is nevertheless capable of conferring an RNA mediated reduced susceptibility of a plant virus in plant cells.
- (2). Constructs according to clause 1, wherein the at least one non-structural gene is a viral gene.
- (3). Multigene DNA constructs comprising at least one non-structural gene wherein the multigene DNA constructs are capable of giving rise to viral elements in plant cells which are capable of conferring a reduced susceptibility to plant viruses in plant cells, and wherein the multigene DNA is under the control of a single set of genetic regulatory elements.
- (4) Constructs according to clauses 2 to 3 comprising at least one viral non-structural gene and one viral structural gene.
- (5) Constructs according to any one of clauses 2 to 4 comprising at least two non-structural genes and no viral structural gene elements.
- (6). Constructs according to clause 5 comprising from 2 to 5 viral non-structural genes.
- (7). Constructs according to any one of clauses 1 to 3 comprising DNA capable of coding for viral RNA molecules of tospoviruses, potyviruses, potexviruses, tobamoviruses, luteoviruses, cucumoviruses, bromoviruses, closteroviruses, tombusviruses, and furoviruses.
- (8) Constructs according to clause 7, wherein the DNA codes for non-structural viral RNA molecules of nucleocapsid proteins, viral coat proteins, and non-structural viral proteins.
- (9). Plants comprising multigene DNA constructs of any one of clauses 1 to 3.
- (10). Plants according to clause 9 selected from the group comprising tomatoes, peppers, melons,

lettuces, cauliflowers, broccolis, cabbages, brussels sprouts, sugar beet, corn (maize), sweetcorn, onions, carrots, leeks, cucumbers, tobacco's alfalfa's, aubergines, beets, broad beans, celery's, chicory's, cow peas, endives, gourds, groundnuts, papayas, peas, peanuts, pineapples, potatoes, safflowers, snap beans, soybeans, spinaches, squashes, sunflowers, water-melons, and sorghums. (11). Plants according to clause 9 selected from the group ornamentals consisting essentially of Impatiens, Begonias, Petunias, Pelargoniums (geraniums), Violas, Cyclamens, Verbenas, Vincas, Tagetes, Primulas, Saint Paulia's Ageratums, Amaranthuses, Anthirrhinums, Aquilegias, Chrysanthemums, Cineraria, Clovers, Cosmos's, Cowpeas, Dahlia's, Daturas, Delphiniums, Gerbera's, Gladioluses, Gloxinias, Hippeastrums, Mesembryanthemums, Salpiglossis, and Zinnias. (12). A method for obtaining plants displaying a reduced susceptibility to viruses which comprises: (a) inserting into the genome of a plant cell a DNA construct according to any one of clauses 1 to 8; (b) obtaining transformed cells; and (c) regenerating from the transformed cells genetically transformed plants.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: Sandoz Ltd
 (B) STREET: Lichtstrasse 35
 (C) CITY: Basel
 (D) STATE: BS
 (E) COUNTRY: Switzerland
 (F) POSTAL CODE (ZIP): CH-4002
 (G) TELEPHONE: 061-324-1111
 (H) TELEFAX: 061-322-7532
 (I) TELEX: 965-05055

(A) NAME: Sandoz Patent GMBH
 (B) STREET: Humboldtstrasse 3
 (C) CITY: Loerach
 (E) COUNTRY: Germany
 (F) POSTAL CODE (ZIP): D-7850

(A) NAME: Sandoz Erfindungen Verwaltungsgesellschaft
 MBH
 (B) STREET: Brunner Strasse
 (C) CITY: Vienna
 (E) COUNTRY: Austria
 (F) POSTAL CODE (ZIP): A-1230

(ii) TITLE OF INVENTION: Virus resistant or tolerant cells

(iii) NUMBER OF SEQUENCES: 5

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
 (B) COMPUTER: IBM PC compatible
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2959 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: unknown

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Chimeric sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GGATCCTGCA GAGCAATTGT GTCAATTTTA TTCAAAAACC TAATACTCAG CAATACAAAT	60
CATCACATTA ACAGGATAAG TAACGACCGC GGTCTACAGT GTTGCACTTT CTCACCTTGA	120
ATCTTATCTC TCGAGAAAGG TCTAGATCTA AACTACCACC ATGTCTAAGG TCAAGCTCAC	180
AAAAGAAAAC ATTGTCTCTC TTTTGACTCA ATCTGAGGAT GTTGAGTTTG AAGAAGACCA	240
GAACCAGGTT GCATTCAACT TTAAGACTTT TTGTCAGGAA AATCTTGACC TGATTAAGAA	300

AATGAGTATC	ACTTCATGTT	TGACTTTCCTT	GAAGAATCGC	CAAAGCATCA	TGAAAGTTGT	360
GAAACAAAGT	GATTTTACTT	TTGGCAAGGT	CACGATAAAG	AAAAATTCAG	AGAGGGTTGA	420
AGCTAAAGAC	ATGACTTTCA	GAAGGCTTGA	TAGCATGATA	AGAGTGAAAC	TCATAGAAGA	480
GACTGCAAAC	AATGAGAATC	TTGCTATCAT	CAAGGCAAAA	ATTGCCTCCC	ATCCTTTGGT	540
CCAAGCTTAC	GGGCTGCCTT	TGGACGATGC	AAAATCTGTG	AGACTTGCCA	TAATGCTTGG	600
AGGTAGTATC	CCTCTCATTG	CTTCTGTTGA	CAGTCTCGAA	ATGATCAGTG	TTGTTCTTGC	660
CATATATCAA	GATAGTCAAG	TACAGGAGTT	AGGGATTGAA	CCAAC TAAGT	ACAACACTAA	720
GGAAGCTCTG	GGGAAGGTTT	GCACTGTGCT	GAAAAGCAAA	GGATTTACAA	TGGATGATGC	780
ACAAGATAAC	AAAGGGAAAG	AATATGCTAA	GATACTCAGT	TCTTGCAATC	CCAATGCTAA	840
GGGAAGCATT	GCTATGGACT	ATTACAGTGA	CAATCTTGAG	AAGTTCATG	AAATGTTTGG	900
AGTCAAGAAA	GAGGCCAAGA	TTGCTGGTGT	TGCATAAAAG	CTTCTTTGTG	TTAATTAAGA	960
GATGCATAAT	ACTAAGTGTG	GGGTACCCTT	AACACTCAGT	CTTACAAATC	ATCACATTAA	1020
GAACCTAAGA	AACGACTGCG	GGATACAGAG	TTGCACTTTC	GCACCTTGAG	TTACATACGG	1080
TCAAAGCATA	TAACAAC TTT	TACGATCATC	ATGTCTAAGG	TTAAGCTCAC	TAAGGAAAGC	1140
ATTGTTGCTT	TGTTGACACA	AGGCAAAGAC	CTTGAGTTTG	AGGAAGATCA	GAATCTGGTA	1200
GCATTCAACT	TCAAGACTTT	TTGTCTGGAA	AACATCGACC	AGATCAAGAA	GATGAGCGTT	1260
ATTTTCATGTC	TGACATT CCT	AAAGAATCGT	CAGAGCATAA	TGAAGGTTAT	TAAGCAAAGC	1320
GATTTTACTT	TTGGTAAAAT	TACCATAAAG	AAAAC TTCAG	ACAGGATTGG	AGGCAC TGAC	1380
ATGACCTTCA	GAAGGCTTGA	TAGCTTGATC	AGGGTCAGGC	TTGTTGAAGA	AACTGGGAAT	1440
TCTGAGAATC	TCAATACTAT	CAAATCTAAG	ATTGCTTCCC	ATCCTTTGAT	TCAAGCCTAT	1500
GGATTACCTC	TCGATGATGC	AAAGTCTGTG	AGACTTGCCA	TAATGCTGGG	AGGTAGCTTA	1560
CCTCTTATTG	CTTCAGTTGA	TAGCTTTGAG	ATGATCAGTG	TTGTCTTGCC	TATATATCAG	1620
GATGCAAAAT	ACAAGGACCT	CGGGATCGAC	CCAAGAAGT	ATGACACCAA	GGAAGCCTTA	1680
GGAAAAGTTT	GCACTGTGCT	GAAAAGCAAA	GCATTTGAAA	TGAATGAAGA	TCAGGTGAAG	1740
AAGGGGAAAG	AGTATGCTGC	TATACTTAGC	TCCAGCAATC	CTAATGCTAA	AGGGAGTGTT	1800
GCTATGGAAC	ATTACAGTGA	AACTCTTAAC	AAGTTCTATG	AAATGTTCCG	GGTTAAAAAG	1860
CAGGCAAAAC	TCGCAGAACT	TGCTTGAAAG	CAGCTGTAAG	TTAAATTATA	AAAAAGCCTA	1920
TAAATATATA	AAGCTTATCG	ATACCGTCGA	CCTCGAGGGG	GGGCCCGGTA	CCGAGCTCGC	1980
TGCAGAGCAA	TTGTGTCAAT	TTTATTCAAA	AACATACTAC	TCAGCAACAC	AAATCATCAC	2040
ATTGCCAGGA	TAAGTAACGA	CTGCGGTCTA	CAGAGTCGTA	CTTCTTACC	TTGAATCACA	2100
TCTCTCGAGA	GCGGTCTAGA	TCTACACTGC	CAAAAATGTC	TAAGGTCAAG	CTCACCAGAG	2160
AGAACATTAT	CTCTCTTCTA	ACTCAGGCTG	GAGAAATCGA	GTTTGAAGAA	GATCAAAATCA	2220
AGGCTACATT	CAACTTCGAA	GACTTTTGCG	GAGAAAATCT	TGATTCAATC	AAGAAAATGA	2280
GCATTACCTC	ATGTTTGACT	TTCCTGAAAA	ATCGCCAGAG	CATCATGAAA	GTTGTGAACC	2340

TTTGTGATTT TACCTTTGGG AAAATCACAA TCAAAAAGAA TTCTGGAAGG GTTGGAGCTA	2400
ATGATATGAC TTTCAGAAGG CTTGATAGCA TGATAAGAGT TAAGCTGATT GAAGAACTG	2460
GAAAAGCAGA AAACCTTGCT ATTATCAAGT CTAAGATTGC CTCTCATCCT CTTGTTCAAG	2520
CTTATGGTCT GCCTCTGACA GATGCAAAGT CTGTAAGGCT TGCCATAATG CTAGGAGGTA	2580
GTATCCCTCT GATTGCTTCT GTGGACAGCT TTGAAATGAT CAGCATCATC CTTGCCATAT	2640
ACCAAGATGC TAAATATAAA GATCTTGGA TTGAACCTTC GAAGTATAAC ACTAAAGAAG	2700
CTTTAGGAAA AGTCTGCACT GTGCTGAAAA GCAAAGGATT TACAATGGAT GAAGAGCAAG	2760
TGCAGAAAGG GAAAGAATAT GCTACAATAC TCAGCTCTTG CAATCCTAAT GCTAAAGGAA	2820
GCATTGCTAT GGAACATTAC AGTGAGCATC TTGACAAATT CTATGCAATG TTCGGAGTAA	2880
GGAAAGAAGC CAAAATTTCA GGTGTTGCAT GAAAGCTTCT TAAAATCTAT TTAAGAGATG	2940
AGTATTGTAG GCGGGATCC	2959

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2899 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: unknown

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: Chimeric sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GGATCCTGCA GAGCAATTGT GTCAATTTTA TTCAAAAACC TAATACTCAG CAATACAAAT	60
CATCACATTA ACAGGATAAG TAACGACCGC GGTCTACAGT GTTGCACTTT CTCACCTTGA	120
ATCTTATCTC TCGAGAAAGG TCTAGATCTA AACTACCACC ATGTCTAAGG TCAAGCTCAC	180
AAAAGAAAAC ATTGTCTCTC TTTTGACTCA ATCTGAGGAT GTTGAGTTTG AAGAAGACCA	240
GAACCAGGTT GCATTCAACT TTAAGACTTT TTGTGAGGAA AATCTTGACC TGATTAAGAA	300
AATGAGTATC ACTTCATGTT TGACTTTCTT GAAGAATCGC CAAAGCATCA TGAAAGTTGT	360
GAAACAAAGT GATTTTACTT TTGGCAAGGT CACGATAAAG AAAAATTCAG AGAGGGTTGA	420
AGCTAAAGAC ATGACTTTCA GAAGGCTTGA TAGCATGATA AGAGTGAAAC TCATAGAAGA	480
GACTGCAAAC AATGAGAATC TTGCTATCAT CAAGGCAAAA ATTGCCTCCC ATCCTTTGGT	540
CCAAGCTTAC GGGCTGCCTT TGGACGATGC AAAATCTGTG AGACTTGCCA TAATGCTTGG	600
AGGTAGTATC CCTCTCATTG CTTCTGTTGA CAGTCTCGAA ATGATCAGTG TTGTTCTTGC	660
CATATATCAA GATAGTCAAG TACAGGAGTT AGGGATTGAA CCAACTAAGT ACAACACTAA	720
GGAAGCTCTG GGAAGGTTT GCACTGTGCT GAAAAGCAAA GGATTTACAA TGGATGATGC	780
ACAAGATAAC AAAGGGAAAG AATATGCTAA GATACTCAGT TCTTGCAATC CCAATGCTAA	840

GGGAAGCATT	GCTATGGACT	ATTACAGTGA	CAATCTTGAG	AAGTTCTATG	AAATGTTTGG	900
AGTCAAGAAA	GAGGCCAAGA	TTGCTGGTGT	TGCATAAAAG	CTTCTTTGTG	TTAATTAAAG	960
GATGCATAAT	ACTAAGTGTG	GGGTACCGGG	CCCCCCCCTG	AGGTCGACGG	TATCGATAAG	1020
CTTGATGTAC	AGTCACCGGA	TGTGCTTTCC	GGTCTGATGA	GTCCGTGAGG	ACGAAACGGT	1080
ATGGTCTAAG	GTTAAGCTCA	CTAAGGAAAG	CATTGTTGCT	TTGTTGACAC	AAGGCAAAGA	1140
CCTTGAGTTT	GAGGAAGATC	AGAATCTGGT	AGCATTCAAC	TTCAAGACTT	TTTGTCTGGA	1200
AAACATCGAC	CAGATCAAGA	AGATGAGCGT	TATTTTCATGT	CTGACATTCC	TAAAGAATCG	1260
TCAGAGCATA	ATGAAGGTTA	TTAAGCAAAG	CGATTTTACT	TTTGGTAAAA	TTACCATAAA	1320
GAAAACCTCA	GACAGGATTG	GAGGCACTGA	CATGACCTTC	AGAAGGCTTG	ATAGCTTGAT	1380
CAGGGTCAGG	CTTGTTGAAG	AAACTGGGAA	TTCTGAGAAT	CTCAATACTA	TCAAATCTAA	1440
GATTGCTTCC	CATCCTTTGA	TTCAAGCCTA	TGGATTACCT	CTCGATGATG	CAAAGTCTGT	1500
GAGACTTGCC	ATAATGCTGG	GAGGTAGCTT	ACCTCTTATT	GCTTCAGTTG	ATAGCTTTGA	1560
GATGATCAGT	GTTGTCTTGG	CTATATATCA	GGATGCAAAA	TACAAGGACC	TCGGGATCGA	1620
CCCAAAGAAG	TATGACACCA	AGGAAGCCTT	AGGAAAAGTT	TGCACTGTGC	TGAAAAGCAA	1680
AGCATTTGAA	ATGAATGAAG	ATCAGGTGAA	GAAGGGGAAA	GAGTATGCTG	CTATACTTAG	1740
CTCCAGCAAT	CCTAATGCTA	AAGGGAGTGT	TGCTATGGAA	CATTACAGTG	AAACTCTTAA	1800
CAAGTTCTAT	GAAATGTTCC	GGGTTAAAAA	GCAGGCAAAA	CTCGCAGAAC	TTGCTTGACC	1860
GTCACCGGAT	GTGCTTTCCG	GTCTGATGAG	TCCGTGAGGA	CGAAACGGTA	CCGAGCTCGC	1920
TGCAGAGCAA	TTGTGTCAAT	TTTATTCAAA	AACATACTAC	TCAGCAACAC	AAATCATCAC	1980
ATTGCCAGGA	TAAGTAACGA	CTGCGGTCTA	CAGAGTCGTA	CTTCTTTACC	TTGAATCACA	2040
TCTCTCGAGA	GCGGTCTAGA	TCTACACTGC	CAAAAATGTC	TAAGGTCAAG	CTCACCAGAG	2100
AGAACATTAT	CTCTCTTCTA	ACTCAGGCTG	GAGAAATCGA	GTTTGAAGAA	GATCAAATCA	2160
AGGCTACATT	CAACTTCGAA	GACTTTTGCG	GAGAAAATCT	TGATTCAATC	AAGAAAATGA	2220
GCATTACCTC	ATGTTTGAAT	TTCCTGAAAA	ATCGCCAGAG	CATCATGAAA	GTTGTGAACC	2280
TTTGTGATTT	TACCTTTGGG	AAAATCACAA	TCAAAAAGAA	TTCTGGAAGG	GTTGGAGCTA	2340
ATGATATGAC	TTTCAGAAGG	CTTGATAGCA	TGATAAGAGT	TAAGCTGATT	GAAGAACTG	2400
GAAAAGCAGA	AAACCTTGCT	ATTATCAAGT	CTAAGATTGC	CTCTCATCCT	CTTGTTCAAG	2460
CTTATGGTCT	GCCTCTGACA	GATGCAAAGT	CTGTAAGGCT	TGCCATAATG	CTAGGAGGTA	2520
GTATCCCTCT	GATTGCTTCT	GTGGACAGCT	TTGAAATGAT	CAGCATCATC	CTTGCCATAT	2580
ACCAAGATGC	TAAATATAAA	GATCTTGGA	TTGAACCTTC	GAAGTATAAC	ACTAAAGAAG	2640
CTTTAGGAAA	AGTCTGCACT	GTGCTGAAAA	GCAAAGGATT	TACAATGGAT	GAAGAGCAAG	2700
TGCAGAAAGG	GAAAGAATAT	GCTACAATAC	TCAGCTCTTG	CAATCCTAAT	GCTAAAGGAA	2760
GCATTGCTAT	GGAACATTAC	AGTGAGCATC	TTGACAAATT	CTATGCAATG	TTCGGAGTAA	2820
GGAAAGAAGC	CAAAATTTCA	GGTGTGTCAT	GAAAGCTTCT	TAAAATCTAT	TTAAGAGATG	2880

AGTATTGTAG GCGGGATCC

2899

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2917 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: unknown

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Chimeric sequence

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CTGCAGAGCA ATTGTGTCAA TTTTATTCAA AAACATACTA CTCAGCAACA CAAATCATCA	60
CATTGCCAGG ATAAGTAACG ACTGCGGTCT ACAGAGTCGT ACTTCTTAC CTTGAATCAC	120
ATCTCTCGAG AGCGGTCTAG ATCTACACTG CCAAAAATGT CTAAGGTCAA GCTCACCAGA	180
GAGAACATTA TCTCTCTTCT AACTCAGGCT GGAGAAATCG AGTTTGAAGA AGATCAAATC	240
AAGGCTACAT TCAACTTCGA AGACTTTTGC GGAGAAAATC TTGATTCAAT CAAGAAAATG	300
AGCATTACCT CATGTTTGAC TTTCTGAAA AATCGCCAGA GCATCATGAA AGTTGTGAAC	360
CTTTGTGATT TTACCTTTGG GAAAATCACA ATCAAAAAGA ATTCTGGAAG GGTGAGCT	420
AATGATATGA CTTTCAGAAG GCTTGATAGC ATGATAAGAG TTAAGCTGAT TGAAGAACT	480
GGAAAAGCAG AAAACCTTGC TATTATCAAG TCTAAGATTG CCTCTCATCC TCTTGTCAA	540
GCTTATGGTC TGCCCTCTGAC AGATGCAAAG TCTGTAAGGC TTGCCATAAT GCTAGGAGGT	600
AGTATCCCTC TGATTGCTTC TGTGGACAGC TTTGAAATGA TCAGCATCAT CCTTGCCATA	660
TACCAAGATG CTAAATATAA AGATCTTGGA ATTGAACCTT CGAAGTATAA CACTAAAGAA	720
GCTTTAGGAA AAGTCTGCAC TGTGCTGAAA AGCAAAGGAT TTACAATGGA TGAAGAGCAA	780
GTGCAGAAAG GGAAAGAATA TGCTACAATA CTCAGCTCTT GCAATCCTAA TGCTAAAGGA	840
AGCATTGCTA TGGAACATTA CAGTGAGCAT CTTGACAAAT TCTATGCAAT GTTCGGAGTA	900
AGGAAAGAAG CCAAAATTTT AGGTGTTGCA TGAAAGCTTC TTAAAATCTA TTTAAGAGAT	960
GAGTATTGTA GGGTACCCTT AACACTCAGT CTTACAAATC ATCACATTAA GAACCTAAGA	1020
AACGACTGCG GGATACAGAG TTGCACTTTC GCACCTTGAG TTACATACGG TCAAAGCATA	1080
TAACAACTTT TACGATCATC ATGTCTAAGG TTAAGCTCAC TAAGGAAAGC ATTGTTGCTT	1140
TGTTGACACA AGGCAAAGAC CTTGAGTTTG AGGAAGATCA GAATCTGGTA GCATTCAACT	1200
TCAAGACTTT TTGTCTGGAA AACATCGACC AGATCAAGAA GATGAGCGTT ATTTTCATGTC	1260
TGACATTCCCT AAAGAATCGT CAGAGCATAA TGAAGGTTAT TAAGCAAAGC GATTTTACTT	1320
TTGGTAAAAT TACCATAAAG AAACTTCAG ACAGGATTGG AGGCACTGAC ATGACCTTCA	1380
GAAGGCTTGA TAGCTTGATC AGGGTCAGGC TTGTTGAAGA AACTGGGAAT TCTGAGAATC	1440

TCAATACTAT CAAATCTAAG ATTGCTTCCC ATCCTTTGAT TCAAGCCTAT GGATTACCTC	1500
TCGATGATGC AAAGTCTGTG AGACTTGCCA TAATGCTGGG AGGTAGCTTA CCTCTTATTG	1560
CTTCAGTTGA TAGCTTTGAG ATGATCAGTG TTGTCTTGGC TATATATCAG GATGCAAAAT	1620
ACAAGGACCT CGGGATCGAC CCAAAGAAGT ATGACACCAA GGAAGCCTTA GGAAAAGTTT	1680
GCACTGTGCT GAAAAGCAAA GCATTTGAAA TGAATGAAGA TCAGGTGAAG AAGGGGAAAG	1740
AGTATGCTGC TATACTTAGC TCCAGCAATC CTAATGCTAA AGGGAGTGTT GCTATGGAAC	1800
ATTACAGTGA AACTCTTAAC AAGTTCTATG AAATGTTCCG GGTAAAAAG CAGGCAAAAC	1860
TCGCAGAACT TGCTTGAAAG CAGCTGTAAG TTAAATTATA AAAAAGCCTA TAAATATATA	1920
AAGCTTATCG ATACCGTCGA CCTCGAGGGG GGGCCCGGTA CCGAGCTCGG TACCCGGGGA	1980
TCCACCATGG GAAATGACAC AATCGATGCA GGAGGAAGCA CTAAGAAAGA TGCAAAACAA	2040
GAGCAAGGTA GCATTCAACC AAATCTCAAC AAGGAAAAGG TAAAGGACGT GAATGTTGGA	2100
ACATCTGGAA CTCACACTGT GCCACGAATT AAAGCTATCA CGTCCAAAAT GAGAATGCCC	2160
AAGAGTAAGG GTGCAACTGT ACTAAATTTG GAACACCTAC TCGAGTATGC TCCACAGCAA	2220
ATTGAAATCT CAAATACTCG AGCAACTCAA TCACAGTTTG ATACATGGTA TGAAGCAGTA	2280
CAACTTGCAT ACGACATAGG AGAAACTGAA ATGCCAACTG TGATGAATGG GCTTATGGTT	2340
TGGTGCAATTG AAAATGGAAC CTCGCCAAAT ATCAATGGAG TTTGGGTAT GATGGATGGA	2400
GATGAACAAG TCGAATACCC AGTGAAACCA ATCGTTGAGA ATGCAAAACC AACACTTAGG	2460
CAAATCATGG CACATTTCTC AGATGTTGCA GAAGCGTATA TAGAAATGCG CAACAAAAAG	2520
GAACCATATA TGCCACGATA TGGTTTAGTT CGTAATCTGC GCGATGGAAG TTTGGCTCGC	2580
TATGCTTTTG ACTTTTATGA AGTTACATCA CGTACACCAG TGAGGGCTAG AGAGGCACAC	2640
ATTCAAATGA AGGCCGAGC TTTAAATCA GCTCAATCTC GACTTTTCGG ATTGGATGGT	2700
GGCATTAGTA CACAAGAGGA AAACACAGAG AGGCACACCA CCGAGGATGT TTCTCCAAGT	2760
ATGCATACTC TACTTGAGT GAAGAACATG TGATTGTAGT GTCTTTCCGG ACGATATATA	2820
GATATTTATG TTTGCAGTAA GTATTTTGGC TTTTCCTGTA CTACTTTTAT CGTAATTAAT	2880
AATCGTTTGA ATCAGATCCT CTAGAGTCCA CCTGCAG	2917

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 75 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: unknown
 - (D) TOPOLOGY: unknown

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Primer

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TGTGGTACCG TCACCGGATG TGCTTTCCGG TCTGATGAGT CCGTGAGGAC GAAACGGTAT 60
GGTCTAAGGT TAAGC 75

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 73 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
(A) ORGANISM: Primer

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATAGGTACCG TTTCGTCCTC ACGGACTCAT CAGACCGGAA AGCACATCCG GTGACGGTCA 60
AGCAAGTTCT GCG 73

CLAIMS

1. A nucleotide sequence comprising a transcriptional regulatory sequence and a sequence contiguous therewith and under the transcriptional control thereof, which contiguous sequence encodes an RNA which consists of a plurality of sub-sequences, characterized in that at least two of the sub-sequences have the sequences of viral RNAs and the RNA contains at least one translational stop codon located upstream of the 3' terminal sub-sequence.
2. A nucleotide sequence according to claim 1, wherein at least one of the sub-sequences is in an anti-sense configuration with respect to virus RNA.
3. A nucleotide sequence according to either of claims 1 or 2, wherein the contiguous sequence encodes mRNA.
4. A nucleotide sequence according to any one of the preceding claims, wherein at least one of the sub-sequences is a cistron.
5. A nucleotide sequence according to any one of the preceding claims, wherein the RNA encoded by the contiguous sequence comprises at least one ribozyme between two of the sub-sequences.
6. A nucleotide sequence according to any preceding claim, wherein at least one of the sub-sequences encodes a viral coat protein or a viral nucleocapsid protein.
7. A nucleotide sequence according to any preceding claim, wherein the contiguous sequence encodes an RNA which comprises at least one sub-sequence derived from viruses selected from the group consisting of tospoviruses, potyviruses, potexviruses, tobamoviruses, luteoviruses, cucumoviruses, bromoviruses, closteroviruses, tombusviruses and furoviruses.
8. A nucleotide sequence which is complementary to one which hybridizes under stringent conditions with the sequence of any one of claims 1 to 7.

9. A DNA construct comprising the nucleotide sequence of any one of claims 1 to 8.
10. A biological vector comprising the nucleotide sequence of any one of claims 1 to 8, or the construct of claim 9.
11. Eukaryotic cells containing the nucleotide sequence according to any one of claims 1 to 8, the construct of claim 9 or the vector according to claim 10
12. Plant cells according to the preceding claim.
13. Plants comprising the cells of the preceding claim, the progeny of such plants which contain the sequence stably incorporated and heritable in a Mendelian manner, and/or the seeds of such plants or such progeny.
14. Use of the sequence according to any one of claims 1 to 8, the construct of claim 9, or the vector according to claim 10 in the production of virus resistant or tolerant eukaryotic cells.
15. Use according to the preceding claim, wherein the cells are plant cells.
16. Use of the sequence according to any one of claims 1 to 8 the construct of claim 9, or the vector according to claim 10 in the production of morphologically normal virus resistant or tolerant whole plants.
17. A method of inducing resistance or tolerance to viruses in eukaryotic cells comprising introducing into such cells a nucleotide sequence according to any one of claims 1 to 8, or a construct according to claim 9, or the vector according to claim 10.
18. A method according to the preceding claim, wherein the cells are plant cells.
19. A method of inhibiting the production of at least one enzyme in a eukaryotic cell comprising introducing into the said cell a nucleotide sequence comprising a transcriptional

regulatory sequence and a sequence contiguous therewith and under the transcriptional control thereof, which contiguous sequence encodes an RNA which consists of a plurality of sub-sequences, characterized in that the RNA encoded by the contiguous sequence contains at least one translational stop codon located upstream of the 3' terminal sub-sequence.

20. A method according to the preceding claim, wherein at least one of the sub-sequences is in an anti-sense configuration with respect to the coding sequence in the host cell mRNA which encodes the said enzyme.




Figure 1




Figure 2

INTERNATIONAL SEARCH REPORT

International Application No

PC./EP 94/03295

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/33 C12N15/11 C12N15/82 C12N5/10 A01H5/00
A01N65/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE,A,40 05 684 (MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.) 29 August 1991	1, 3, 4, 6-18
Y	see the claims.	2, 5, 19, 20
X	EMBO J., vol.3, 1984 pages 2731 - 2736 L.K. DIXON AND T. HOHN 'initiation of translation of the cauliflower mosaic virus genome from a polycistronic mRNA: evidence from deletion mutagenesis' see the whole document.	1, 3, 4, 6, 8-13

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

1 February 1995

Date of mailing of the international search report

23. 02. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Yeats, S

INTERNATIONAL SEARCH REPORT

International Application No
PC/EP 94/03295

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. VIROL., vol.66, 1992 pages 3131 - 3139 H.B. SCHOLTHOF ET AL.; 'The full-length transcript of a caulimovirus is a polycistronic mRNA whose genes are trans activated by the product of gene VI' see the whole document. ---	1,3,4,6, 8-13
X	THE PLANT CELL, vol.1, 1989 pages 1057 - 1067 L. HANLEY-BOWDOIN ET AL.; 'Functional expression of the leftward open reading frames of the A component of tomato golden mosaic virus in transgenic tobacco plants' see the whole document. ---	1,3,4,6, 8-13
X	WO,A,93 03143 (ANDERSON, W. ET AL.) 18 February 1993 see the whole document. ---	1,3,4, 8-11
X	WO,A,92 19752 (TRANSGENE S.A.) 12 November 1992 see the claims. ---	1,3,4, 8-11
X	J. MOL. BIOL., vol.148, 1981 pages 303 - 330 J.J. DUNN AND F.W. STUDIER; 'Nucleotide sequence from the genetic left end of bacteriophage T7 DNA to the beginning of gene 4' see the abstract and pages 324-325. ---	1,3,4, 8-10
Y	WO,A,93 14210 (SANDOZ-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H) 22 July 1993 see the claims. ---	2,5,19, 20
Y	EP,A,0 421 376 (HOECHST AKTIENGESELLSCHAFT) 10 April 1991 see the claims. ---	2,5,19, 20
A	BIO/TECHNOLOGY, vol.10, 1992 pages 1133 - 1137 P. DE HAAN ET AL.; 'Characterization of RNA-mediated resistance to tomato spotted wilt virus in transgenic tobacco plants' see the whole document. ---	1
1 A	WO,A,93 17098 (THE STATE OF OREGON) 2 September 1993 see the claims. -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC1/EP 94/03295

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE-A-4005684	29-08-91	NONE	
WO-A-9303143	18-02-93	CA-A- 2114416 EP-A- 0598029 JP-T- 6509713	18-02-93 25-05-94 02-11-94
WO-A-9219752	12-11-92	FR-A- 2676072 AU-B- 652831 AU-A- 1768192 EP-A- 0537326 JP-T- 6502998	06-11-92 08-09-94 21-12-92 21-04-93 07-04-94
WO-A-9314210	22-07-93	NONE	
EP-A-0421376	10-04-91	DE-A- 3933384 AU-B- 634289 AU-A- 6382790 HU-A- 62038 JP-A- 3210180	18-04-91 18-02-93 11-04-91 29-03-93 13-09-91
WO-A-9317098	02-09-93	CA-A- 2130454 EP-A- 0626998 NO-A- 943038	02-09-93 07-12-94 17-10-94